Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Merck USA (MSD) acquires Phase 2 biotech for US$ 10.8 Bln.

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Apr 16, 2023 11:47am

104 Views

Post# 35397280

RE:RE:Merck USA (MSD) acquires Phase 2 biotech for US$ 10.8 Bln.

The how is in the same way that the biotech Exelixis reached US$9.9 Billion of market cap in 2017 from a share price of US$1.33 share in 2015.

And part of the how is that ONCY has a final Phase 2 readout of the Bracelet-1 breast cancer clinical study to be made at an upcoming major medical conference in the next 2 months.

<< Previous

Bullboard Posts

Next >>

Golden Minerals closes Yoquivo gold-silver project sale